 JACKSON CENTER, PA ACCESSWIRE March 2, 2021 Halberd Corp. OTC PINK:HALB has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV-2 Spike protein. Dr. Reyes, Halberds Chief Technical Officer, indicated, Our latest results indicate increased specificity of our second antibody, which can be used as a stand-alone or in combination with other antibodies for the overall optimum management of COVID-19. 